论文部分内容阅读
目的观察肺表面活性物质预防新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法选取2012年4月-2014年2月收治的存在呼吸困难症状的早产儿68例,随机分为观察组35例和对照组33例。对照组给予常规治疗,观察组在常规治疗基础上给予肺表面活性物质治疗,对比2组患儿治疗效果及并发症发生情况。结果观察组NRDS发生率、并发症发生率及出现呼吸急促、发绀症状发生率均显著低于对照组(P<0.05);血气分析显示观察组Pa O2及p H显著高于对照组,Pa CO2显著低于对照组,差异均有统计学意义(P<0.05)。结论肺表面活性物质对NRDS有显著预防效果,可促使并发症发生率大大降低,值得在临床中推广。
Objective To observe the clinical efficacy of pulmonary surfactant in the prevention of neonatal respiratory distress syndrome (NRDS). Methods Sixty-eight premature infants with dyspnea who were admitted to our hospital from April 2012 to February 2014 were randomly divided into observation group (35 cases) and control group (33 cases). The control group was given routine treatment. The observation group was given pulmonary surfactant treatment on the basis of routine treatment. The therapeutic effect and complication of the two groups were compared. Results The incidence of NRDS, the incidence of complications and the occurrence of shortness of breath and cyanosis in observation group were significantly lower than those in control group (P <0.05). The blood gas analysis showed that Pa O2 and p H in observation group were significantly higher than those in control group and Pa CO2 Significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Pulmonary surfactant has a significant preventive effect on NRDS, which can greatly reduce the incidence of complications and is worth popularizing in clinic.